Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Learn which cash back cards are best this year and make informed decisions for your spending. Start saving today!
27,489 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Solana is testing the Alpenglow upgrade with validator trials and a potential Q3 mainnet. Analysts weigh timing, risk...
A major tech giant has locked in a multi-year AI compute deal worth nearly $1 billion per month for Nvidia GPUs, outp...
A rare mother-son royal outing highlights budgeting basics families can use for big days out. Learn how to plan, save...
Hyperliquid’s hip-3 markets surge has pushed HIP-3’s share of perpetual futures volume to roughly half, signaling a d...
Volatility feels rough, but it isn’t deadly. This guide shows why panic selling costs investors more than a market tu...
Ethereum sits in a tight range while on-chain tokenized Treasuries on the network surpass $8 billion, marking a major...
Prices are cooling in five metro areas as listings with price reductions rise. Here's what buyers and sellers should ...
As AI hardware demand strengthens, the buy everything ai strategy draws renewed attention. AIQ has posted double-digi...
Nvidia stands at a crossroads: rising Chinese demand for AI GPUs could lift sales, but policy risks and fierce compet...
A newly installed Fed chair faces a murky policy path as inflation cools. With a split committee and mixed data, kevi...
Oil prices jump again, fueling fears of broader economic stress as supply constraints and demand resilience push benc...